Across TCGA pan-cancer cohorts, BCAP31 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BCAP31 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher BCAP31 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCAP31 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, BLCA, and SKCM are the cancer types where BCAP31 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	All	0.168	0.541	.005	18	view →
BLCA	OS	Median	III,IV	0.133	0.684	<.001	18	view →
SKCM	DFS	Median	All	0.237	0.760	.004	17	view →
LIHC	OS	Median	All	0.025	0.777	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.633	.021	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: BCAP31 tumor-vs-normal RNA expression · all BCAP31 data types